Research and Markets: Ovarian Cancer - Pipeline Review, H1 2012

Research and Markets has announced the addition of Global Markets Direct's new report "Ovarian Cancer - Pipeline

Ovarian Cancer Canada embarks on Atlantic campaign

The advocacy group Ovarian Cancer Canada is looking to extend its reach deeper into Atlantic Canada.

Gene Mutations May Boost Ovarian Cancer Survival: Study

TUESDAY, Jan. 24 (HealthDay News) -- Genetic mutations known as BRCA1 and BRCA2 raise the risk of getting ovarian cancer, but new research shows that those same mutations may boost a woman's odds of surviving the deadly disease.

Women with Certain Type of Ovarian Cancer and BRCA Gene Mutation Have Improved Survival at 5 Years

Among women with invasive epithelial ovarian cancer, patients having a germline (gene change in a reproductive cell that could be passed to offspring) mutation in the BRCA1 or BRCA2 genes was associated with improved 5-year overall survival, with BRCA2 carriers having the best prognosis, according to a study in the January 25 issue of JAMA.

'DIMming' cancer growth -- STAT: Diindolylmethane suppresses ovarian cancer

Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane (DIM) has been shown in laboratory to inhibit the growth of ovarian cancer cells. New research published in BioMed Central's open access journal BMC Medicine has ...